Detailed entry information

Protein Information (annotations from UniProt)

Database IDHIV0012483
UniProt IDP08581
Primary gene name(s)MET
Synonym gene name(s)unknown
Protein nameHepatocyte growth factor receptor
Protein functionReceptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to hepatocyte growth factor/HGF ligand. Regulates many physiological processes including proliferation, scattering, morphogenesis and survival. Ligand binding at the cell surface induces autophosphorylation of MET on its intracellular domain that provides docking sites for downstream signaling molecules. Following activation by ligand, interacts with the PI3-kinase subunit PIK3R1, PLCG1, SRC, GRB2, STAT3 or the adapter GAB1. Recruitment of these downstream effectors by MET leads to the activation of several signaling cascades including the RAS-ERK, PI3 kinase-AKT, or PLCgamma-PKC. The RAS-ERK activation is associated with the morphogenetic effects while PI3K/AKT coordinates prosurvival effects. During embryonic development, MET signaling plays a role in gastrulation, development and migration of muscles and neuronal precursors, angiogenesis and kidney formation. In adults, participates in wound healing as well as organ regeneration and tissue remodeling. Promotes also differentiation and proliferation of hematopoietic cells. May regulate cortical bone osteogenesis, By similarity. {ECO:0000250|UniProtKB:P16056}.; FUNCTION: Acts as a receptor for Listeria internalin inlB, mediating entry of the pathogen into cells.
Subcellular locationMembrane;
Single-pass type I membrane protein.;
SUBCELLULAR LOCATION: Isoform 3: Secreted.
ECO codeClick here for more information.
Amino acid sequence
FASTA format: P08581
Gene Ontology
(Biological Process)
Complete annatation
branching morphogenesis of an epithelial tube [GO:0048754];
cell proliferation [GO:0008283];
cell surface receptor signaling pathway [GO:0007166];
endothelial cell morphogenesis [GO:0001886];
negative regulation of autophagy [GO:0010507];
negative regulation of hydrogen peroxide-mediated programmed cell death [GO:1901299];
positive chemotaxis [GO:0050918];
positive regulation of endothelial cell chemotaxis [GO:2001028];
positive regulation of transcription from RNA polymerase II promoter [GO:0045944];
semaphorin-plexin signaling pathway [GO:0071526];
signal transduction [GO:0007165]
Gene Ontology
(Molecular Function)
Complete annatation
ATP binding [GO:0005524];
hepatocyte growth factor-activated receptor activity [GO:0005008];
protein phosphatase binding [GO:0019903];
protein tyrosine kinase activity [GO:0004713]
Gene Ontology
(Cellular Component)
Complete annatation
basal plasma membrane [GO:0009925];
cell surface [GO:0009986];
extracellular region [GO:0005576];
integral component of membrane [GO:0016021];
integral component of plasma membrane [GO:0005887];
plasma membrane [GO:0005886]
Protein-protein interaction110391
Phylogenetic treeP08581
HIV replication factor status Zhou et al., Cell. Host. Microbe., 2008
      unknown
Brass et al., Science, 2008
      unknown
Smith et al., J. Immunol, 2010
      Negatively associated
Interferon-stimulated
gene status
Lu et al., J. Virol., 2011
      Folds changes 8h: unknown; Folds changes 16h: unknown; Tested: unknown;
Schoggins JW and Rice CM, Curr. Opin. Virol., 2011
      Targeted viruses: unknown
      Viral life cycle: unknown
      Mechanism related to antiviral activity: unknown
Anti-viral restriction factor Liu et al., Retrovirology, 2011
      unknown (Triplicates)

Gene Expression Profile       top

            Up-regulated;            Down-regulated

For brief introduction to each study, please go to the help page.

Gene expression during HIV latency

(1). Mohammadi et al., PLoS Pathog., 2014

Differentially expressed transcripts (Pairwise) during latency and subsequent viral reactivation using several agents - Primary CD4+ T-cell based model


DMSO: Dimethyl suloxyde (negative control) - 0.0033% final
SAHA: Vorinostat (Histone deacetylase inhibitor) - 0.5 μM
CD3: TCR Stimulation by IL-2+ antiCD3/anti-CD28 antibodies
IL7: Interleukin-7 based stimulation
DISU: Disulfiram (alcohol dehydrogenase inhibitor) - 0.5 μM
AZA: 5-azacytidine (AZA; DNA methylation inhibitor) - 1 μM
Experimental Condition Log2 Fold Change P value Adjusted P value
AZA vs. CD3-0.3887024931023710.6115744298271310.714380361648804
AZA vs. DISU-0.3498904648795550.6716992910850090.964028859736782
AZA vs. IL7-0.3312998865041180.654076643787370.999311006273513
AZA vs. SAHA-0.2528890960423190.7422941494987360.928636130159406
DISU vs. CD30.02585162936015360.9743915980004510.984030169178238
DISU vs. IL70.009601697319801990.9899187063375870.999065831444279
DISU vs. SAHA0.0964572153498320.9026340054061940.97663845900472
DMSO vs. AZA0.008440476862267950.9912619386694651
DMSO vs. CD30.3819270877078240.5827752520269390.681482044512507
DMSO vs. DISU0.3551514826576960.6522295553050960.949713766615536
DMSO vs. IL7-0.3317624013404680.6321845222500810.920378169311359
DMSO vs. SAHA-0.2688881239579550.7106849890339880.913028170636027
HIV vs. Mock in Activation-0.5801948761373280.4999676941519990.999983755607037
HIV vs. Mock in Latency-0.138199331325690.8591809478119320.999834320637052
IL7 vs. CD30.06615881508041210.9190627893815330.948837905777249
SAHA vs. CD30.1077042867578540.8760473961623050.913214202589071
SAHA vs. IL70.07278402342954820.9160734704436030.968167318220946
(2). Iglesias-Ussel et al., J. Virol., 2013

Up and Downregulated transcripts during Latency (Latently infected CD4+ T cells vs Uninfected)- Primary CD4+Tcell based model
Log2 Fold Change P Value
unknown unknown

Gene expression during HIV infection and replication

(1). Imbeault et al., PloS Pathog., 2012

Transcriptomic profiling of HIV-1 infected CD4+ T cells - Primary CD4+ T cells
Experiment type Log2 Fold Change P Value Adjusted P Value
Infected vs. Mock unknown unknown unknown
Infected vs. Bystander unknown unknown unknown
(2). Lefebvre et al., J. Virol., 2011

Transcriptome analysis of T-cell line (Sup T1)
Log2 Fold Change unknown
(3). Li et al., J. Immunol., 2013

Lymphatic tissue
Acute Fold Change Acute P Value Asymt Fold Change Asypt P Value AIDS Fold Change AIDS P Value
-1.5 0.028642929 -1.6 0.011209712 -1.7 0.007262318
(4). Chang et al., MBio., 2011

Transcriptome analysis of T-cell line (Sup T1)

Derived from Sherrill-Mix et al., BMC Retrovirol., 2015 cross validation
Up-regulated (True) unknown
(5). Sherrill-Mix et al., BMC Retrovirol., 2015

Deep RNA-seq analysis of primary human T cell infected with low passage HIV isolate HIV89.6 - Primary CD4+ T cell based
Test Status Log2 Fold Change P Value
OK 0.918591 0.000305467
(6). Rotger et al., PLoS Pathog., 2010

Genome-wide mRNA expression of CD4+ T cells from HIV-infected patient
(Genes differentially expressed (at adjusted p<0.01) according to the empirical Bayes approach)
Log2 Fold Change P Value
unknown unknown

Proteomic/Transcriptomics studies indicating differentially expressed genes mediated by HIV

(1). Greenwood et al., Elife, 2016

Activated (CD3/CD28) Primary human CD4+ T cells infected with pNL4-3-dE-EGFP. The table shows the complete (unfiltered) TMT (tandem mass tag)-based proteomic time course dataset
6 h 24 h 48 h 72 h RTi
unknown unknown unknown unknown unknown
(2). Navare et al., Virology, 2012

SUP-T1 cell line
FC-4hpi P-value FC-8hpi P-value FC-20hpi P-value Category
unknown unknown unknown unknown unknown unknown unknown
(3). Hyrcza et al., J. Virolo., 2007

Primary human CD4+ and CD8+ T Cells
Affymetrix Prob ID Fold Change In CD8? Category
unknown unknown unknown unknown

Protein Overview       top

Drug-protein Interaction       (annotations from DrugBank)      top

Drugbank ID Drug Name Drug Status Pharmacological Action Drug Action
DB02152 K-252a experimental unknown unknown
DB05216 MP470 investigational unknown unknown
DB05153 XL184 investigational unknown unknown
DB06896 1-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-2-oxo-1,2-dihydropyridine-3-carboxamide experimental unknown unknown
DB06995 N-({4-[(2-aminopyridin-4-yl)oxy]-3-fluorophenyl}carbamoyl)-2-(4-fluorophenyl)acetamide experimental unknown unknown
DB06997 2-(4-fluorophenyl)-N-{[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]carbamoyl}acetamide experimental unknown unknown
DB07369 N-(3-chlorophenyl)-N-methyl-2-oxo-3-[(3,4,5-trimethyl-1H-pyrrol-2-yl)methyl]-2H-indole-5-sulfonamide experimental unknown unknown
DB07969 3-[3-(4-methylpiperazin-1-yl)-7-(trifluoromethyl)quinoxalin-5-yl]phenol experimental unknown unknown
DB08584 6-{[6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl}quinoline experimental unknown unknown
DB08700 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-amine experimental unknown unknown
DB08791 1-[(2-NITROPHENYL)SULFONYL]-1H-PYRROLO[3,2-B]PYRIDINE-6-CARBOXAMIDE experimental unknown unknown
DB08875 Cabozantinib approved yes antagonist
DB08865 Crizotinib approved yes inhibitor

Protein Secondary Structure       (annotations from PDB)      top

PDB Accession Method Resolution Chain Structure Preview
1FYR X-ray 2.4Å I/J/K/L=1356-1359.
1R0P X-ray 1.8Å A=1049-1360.
1R1W X-ray 1.8Å A=1049-1360.
1SHY X-ray 3.2Å B=25-567.
1SSL NMR - A=519-562.
1UX3 Model - A=25-656.
2G15 X-ray 2.1Å A=1038-1346.
2RFN X-ray 2.5Å A/B=1048-1351.
2RFS X-ray 2.2Å A=1048-1351.
2UZX X-ray 2.8Å B/D=25-740.
2UZY X-ray 4.0Å B/D=25-740.
2WD1 X-ray 2.0Å A=1055-1346.
2WGJ X-ray 2.0Å A=1051-1348.
2WKM X-ray 2.2Å A=1051-1348.
3A4P X-ray 2.5Å A=1049-1360.
3BUX X-ray 1.3Å A/C=997-1009.
3C1X X-ray 2.1Å A=1049-1360.
3CCN X-ray 1.9Å A=1048-1350.
3CD8 X-ray 2.0Å A=1048-1350.
3CE3 X-ray 2.4Å A=1049-1360.
3CTH X-ray 2.3Å A=1049-1360.
3CTJ X-ray 2.5Å A=1049-1360.
3DKC X-ray 1.5Å A=1049-1360.
3DKF X-ray 1.8Å A=1049-1360.
3DKG X-ray 1.9Å A=1049-1360.
3EFJ X-ray 2.6Å A/B=1048-1351.
3EFK X-ray 2.2Å A/B=1048-1351.
3F66 X-ray 1.4Å A/B=1052-1349.
3F82 X-ray 2.5Å A=1049-1360.
3I5N X-ray 2.0Å A=1048-1350.
3L8V X-ray 2.4Å A=1049-1360.
3LQ8 X-ray 2.0Å A=1051-1348.
3Q6U X-ray 1.6Å A=1048-1348.
3Q6W X-ray 1.7Å A=1048-1348.
3QTI X-ray 2.0Å A/B=1050-1360.
3R7O X-ray 2.3Å A=1048-1348.
3RHK X-ray 1.9Å A/B=1038-1346.
3U6H X-ray 2.0Å A=1048-1351.
3U6I X-ray 2.1Å A=1048-1351.
3VW8 X-ray 2.1Å A=1024-1352.
3ZBX X-ray 2.2Å A=1051-1348.
3ZC5 X-ray 2.2Å A=1051-1348.
3ZCL X-ray 1.4Å A=1051-1348.
3ZXZ X-ray 1.8Å A=1051-1348.
3ZZE X-ray 1.8Å A=1051-1348.
4AOI X-ray 1.9Å A=1051-1348.
4AP7 X-ray 1.8Å A=1051-1348.
4DEG X-ray 2.0Å A=1048-1351.
4DEH X-ray 2.0Å A=1048-1351.
4DEI X-ray 2.0Å A=1048-1351.
4EEV X-ray 1.8Å A=1038-1346.
4GG5 X-ray 2.4Å A=1038-1346.
4GG7 X-ray 2.2Å A=1038-1346.
4IWD X-ray 1.9Å A=1048-1348.
4K3J X-ray 2.8Å B=39-564.
4KNB X-ray 2.4Å A/B/C/D=1060-1346.
4MXC X-ray 1.6Å A=1038-1346.
4O3T X-ray 2.9Å B=25-567.
4O3U X-ray 3.0Å B=25-567.
4R1V X-ray 1.2Å A=1055-1345.
4R1Y X-ray 2.0Å A=1055-1346.
4XMO X-ray 1.7Å A=1048-1350.
4XYF X-ray 1.8Å A=1048-1351.
5DG5 X-ray 2.6Å A/B=1038-1346.
5EOB X-ray 1.7Å A=1038-1346.
5EYC X-ray 1.8Å A=1048-1351.
5EYD X-ray 1.8Å A=1048-1351.
5T3Q X-ray 2.0Å A=1048-1350.

HIV-1 Interaction       (annotations from NCBI HIV-1 Interaction Database)      top

not found

Metabolic/Signalling Pathway       (annotations from KEGG database)      top

Pathway Accession Number Description
hsa01521 EGFR tyrosine kinase inhibitor resistance - Homo sapiens (human)
hsa04014 Ras signaling pathway - Homo sapiens (human)
hsa04015 Rap1 signaling pathway - Homo sapiens (human)
hsa04060 Cytokine-cytokine receptor interaction - Homo sapiens (human)
hsa04144 Endocytosis - Homo sapiens (human)
hsa04151 PI3K-Akt signaling pathway - Homo sapiens (human)
hsa04360 Axon guidance - Homo sapiens (human)
hsa04510 Focal adhesion - Homo sapiens (human)
hsa04520 Adherens junction - Homo sapiens (human)
hsa05100 Bacterial invasion of epithelial cells - Homo sapiens (human)
hsa05120 Epithelial cell signaling in Helicobacter pylori infection - Homo sapiens (human)
hsa05144 Malaria - Homo sapiens (human)
hsa05200 Pathways in cancer - Homo sapiens (human)
hsa05202 Transcriptional misregulation in cancer - Homo sapiens (human)
hsa05205 Proteoglycans in cancer - Homo sapiens (human)
hsa05206 MicroRNAs in cancer - Homo sapiens (human)
hsa05211 Renal cell carcinoma - Homo sapiens (human)
hsa05218 Melanoma - Homo sapiens (human)
hsa05230 Central carbon metabolism in cancer - Homo sapiens (human)
Menu